CCL5 and osteosarcoma: Pretreatment of cells with PI3K (Ly294002), Akt (Akt inhibitor), or PKCδ (Rottlerin) inhibitor partially reduced CCL5-induced cell migration in osteosarcoma cells (Figure S1).